Disease Overview
Acute HCV Infection
- First 6 months after infection
- >60% asymptomatic
- 25-35% experience symptoms
- 15-45% spontaneous clearance
Chronic HCV Infection
- Persists >6 months after infection
- 55-85% of acute cases progress
- Rare spontaneous resolution
- Leads to serious complications
Natural History of Hepatitis C Infection
Timeline showing progression from acute infection to chronic disease and potential complications
Transmission Routes
Primary Transmission Mechanism
Hepatitis C virus (HCV) is transmitted by contact with infected blood or blood-derived products.
Parenteral Transmission
- Most common route in UK
- Needle sharing in PWID
- Blood transfusions (pre-1991)
- Medical equipment reuse
- Needlestick injuries
- Personal item sharing
- Tattooing & body piercing
Sexual Transmission
- Infrequent in monogamous relationships
- Increased risk with multiple partners
- Higher in HIV-positive individuals
- MSM at increased risk
- Risky sexual practices
- Anal sex higher risk
Vertical Transmission
- Mother to baby
- Generally low transmission rate
- Timing during pregnancy/birth
- Maternal viral load factor
- Breastfeeding considerations
High-Risk Settings
In developing countries, routine injections and medical/dental procedures may confer high cumulative lifetime risk due to inadequate sterile supplies.
Clinical Features
Note: Only 25-35% of people experience symptoms in early stages, and infection occurs after incubation period. Patients may not connect symptoms to exposure time.
General Symptoms
- Non-specific fatigue
- Myalgia (muscle pain)
- Anxiety and depression
- Poor memory/concentration
- Nausea and vomiting
Hepatic Symptoms
- Right upper quadrant pain
- Jaundice
- Dark urine
- Pale stools (if cholestasis)
- Hepatomegaly
Advanced Disease
- Signs of chronic liver disease
- Spider naevi
- Palmar erythema
- Ascites
- Hepatic encephalopathy
Symptom Timeline After Exposure
Incubation period and symptom development pattern following HCV exposure
Diagnosis & Testing
Initial Screening
- HCV Antibody Test
- Indicates past or present infection
- Positive if ever infected
- Does not differentiate acute/chronic
- Window period: 4-10 weeks
Confirmatory Tests
- HCV RNA Test
- Confirms active infection
- Quantitative viral load
- Genotype analysis
- Treatment monitoring
Additional Investigations
- Liver function tests (LFTs)
- Liver ultrasound
- Fibrosis assessment (FibroScan)
- HIV/HBV co-infection testing
- Complete blood count
Diagnostic Algorithm for HCV
Step-by-step diagnostic pathway from screening to confirmation and genotyping
Management & Referral
Urgent Referral Criteria
- Suspected acute HCV: Same-day assessment or immediate specialist advice
- HCV antibody positive + acute hepatitis features
- Recent identified transmission source
Chronic HCV Referral
- Urgent referral for chronic HCV suspicion
- HCV antibody positive + RNA positive
- No clinical features of acute hepatitis
Patient Advice & Education
Disease Progression
- Smoking cessation
- Alcohol avoidance
- Healthy lifestyle
- Vaccination (Hep A/B)
Infection Control
- No sharing personal items
- Safe sex practices
- Needle disposal safety
- Blood spill management
Public Health
- Partner notification
- Contact tracing
- Health Protection Team notification
- Support services information
Specialist Treatment
Treatment Approach
Acute Infection
- 15-45% spontaneous clearance
- Monitor for 6 months
- Early treatment if no clearance
- Higher success rates in acute phase
- Reduces chronic progression risk
Chronic Infection
- All patients considered for treatment
- Specialist initiation only
- Goal: viral eradication
- Sustained virological response (SVR)
- SVR = cure equivalent
Direct-Acting Antivirals (DAAs)
| Treatment Factor | Considerations |
|---|---|
| HCV Genotype | Determines specific DAA regimen |
| Viral Load | Baseline and monitoring during treatment |
| Liver Disease Severity | Fibrosis stage, cirrhosis presence |
| Treatment History | Previous HCV treatment response |
| Comorbidities | Renal function, HIV/HBV coinfection |
| Treatment Tolerance | Side effect management |
Treatment Success
- >90% success rate with DAAs
- Target different HCV lifecycle stages
- Well-tolerated oral regimens
- Shorter treatment durations (8-24 weeks)
- Minimal side effects
Complications
Acute Complications
- Fulminant Hepatitis
- Rare (<1% of cases)
- Acute liver failure
- Rapid progression
- High mortality without transplant
Chronic Complications
- Liver Cirrhosis
- 20-30% of chronic cases
- Over 20-30 year period
- Progressive fibrosis
- Portal hypertension
Long-term Risks
- Hepatocellular Carcinoma
- Annual risk 1-5% in cirrhosis
- Leading cause of liver cancer
- Regular surveillance needed
- Liver failure development
Complication Progression Timeline
Long-term progression from chronic infection to cirrhosis and hepatocellular carcinoma
Risk Factors for Progression
Male gender
Older age at infection
Alcohol consumption
HIV coinfection
Obesity/Diabetes
Smoking